Immunomodulatory kits generating leukaemia derived dendritic cells do not induce blast proliferation ex vivo: IPO-38 as a novel marker to quantify proliferating blasts in acute myeloid leukaemia

Plett, Caroline; Klauer, Lara Kristina; Amberger, Daniel Christoph; Ugur, Selda; Rabe, Alexander; Fischer, Zuzana; Deen, Diana; Hirn-Lopez, Annika; Gunsilius, Carina; Werner, Jan-Ole; Schmohl, Jörg; Kramer, Doris; Rank, Andreas; Schmid, Christoph und Schmetzer, Helga Maria (2022): Immunomodulatory kits generating leukaemia derived dendritic cells do not induce blast proliferation ex vivo: IPO-38 as a novel marker to quantify proliferating blasts in acute myeloid leukaemia. In: Clinical Immunology, Vol. 242, 109083

Abstract

(Leukaemia derived) dendritic cells (DC, DCleu) are potent stimulators of anti-leukaemic activity in acute myeloid leukaemia (AML) and can be generated with immunomodulatory kits containing granulocyte-macrophage -colony-stimulating-factor (GM-CSF), prostaglandin-E-1 (PGE1), prostaglandin-E-2 (PGE2) and/or picibanil (OK -321). Potential adverse effects initiated through kits, especially the proliferation of blasts, must be ruled out to ensure treatment safety. We quantified proliferating blasts with the proliferation markers CD71 and Ki-67 and the novel proliferation marker IPO-38 before and after kit treatment ex vivo. IPO-38 hereby appeared to be the most sensitive marker;a combination with CD71 may add value when assessing proliferation kinetics. Kit treatment did not or only slightly (< 5%) induce blast proliferation in most cases. An induction of blast prolif-eration was only found in single cases and could be compensated by DCleu-induced anti-leukaemic activity in most times. Overall, we appraise kit treatment to be safe in vivo.

• Item Type: Journal article
• Faculties: Medicine
• Subjects: 600 Technology > 610 Medicine and health
• ISSN: 1521-6616
• Language: English